Identification of novel DNA methylation inhibitors via a two-component reporter gene system
<p>Abstract</p> <p>Background</p> <p>Targeting abnormal DNA methylation represents a therapeutically relevant strategy for cancer treatment as demonstrated by the US Food and Drug Administration approval of the DNA methyltransferase inhibitors azacytidine and 5-aza-2�...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-01-01
|
| Series: | Journal of Biomedical Science |
| Online Access: | http://www.jbiomedsci.com/content/18/1/3 |
| _version_ | 1819029113510297600 |
|---|---|
| author | Chen Ching-Shih Huang Tim HM Tseng Min-Jen Teng I-Wen Hsu Chia-Chen Wang Shi-Gang Shaw Arthur Y Lin Yi-Shiuan Leu Yu-Wei Hsiao Shu-Huei |
| author_facet | Chen Ching-Shih Huang Tim HM Tseng Min-Jen Teng I-Wen Hsu Chia-Chen Wang Shi-Gang Shaw Arthur Y Lin Yi-Shiuan Leu Yu-Wei Hsiao Shu-Huei |
| author_sort | Chen Ching-Shih |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Targeting abnormal DNA methylation represents a therapeutically relevant strategy for cancer treatment as demonstrated by the US Food and Drug Administration approval of the DNA methyltransferase inhibitors azacytidine and 5-aza-2'-deoxycytidine for the treatment of myelodysplastic syndromes. But their use is associated with increased incidences of bone marrow suppression. Alternatively, procainamide has emerged as a potential DNA demethylating agent for clinical translation. While procainamide is much safer than 5-aza-2'-deoxycytidine, it requires high concentrations to be effective in DNA demethylation in suppressing cancer cell growth. Thus, our laboratories have embarked on the pharmacological exploitation of procainamide to develop potent DNA methylation inhibitors through lead optimization.</p> <p>Methods</p> <p>We report the use of a DNA methylation two-component enhanced green fluorescent protein reporter system as a screening platform to identify novel DNA methylation inhibitors from a compound library containing procainamide derivatives.</p> <p>Results</p> <p>A lead agent IM25, which exhibits substantially higher potency in <it>GSTp1 </it>DNA demethylation with lower cytotoxicity in MCF7 cells relative to procainamide and 5-aza-2'-deoxycytidine, was identified by the screening platform.</p> <p>Conclusions</p> <p>Our data provide a proof-of-concept that procainamide could be pharmacologically exploited to develop novel DNA methylation inhibitors, of which the translational potential in cancer therapy/prevention is currently under investigation.</p> |
| first_indexed | 2024-12-21T06:09:06Z |
| format | Article |
| id | doaj.art-55d5369117f748da8a2ce37bf2d5ffc9 |
| institution | Directory Open Access Journal |
| issn | 1021-7770 1423-0127 |
| language | English |
| last_indexed | 2024-12-21T06:09:06Z |
| publishDate | 2011-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Biomedical Science |
| spelling | doaj.art-55d5369117f748da8a2ce37bf2d5ffc92022-12-21T19:13:34ZengBMCJournal of Biomedical Science1021-77701423-01272011-01-01181310.1186/1423-0127-18-3Identification of novel DNA methylation inhibitors via a two-component reporter gene systemChen Ching-ShihHuang Tim HMTseng Min-JenTeng I-WenHsu Chia-ChenWang Shi-GangShaw Arthur YLin Yi-ShiuanLeu Yu-WeiHsiao Shu-Huei<p>Abstract</p> <p>Background</p> <p>Targeting abnormal DNA methylation represents a therapeutically relevant strategy for cancer treatment as demonstrated by the US Food and Drug Administration approval of the DNA methyltransferase inhibitors azacytidine and 5-aza-2'-deoxycytidine for the treatment of myelodysplastic syndromes. But their use is associated with increased incidences of bone marrow suppression. Alternatively, procainamide has emerged as a potential DNA demethylating agent for clinical translation. While procainamide is much safer than 5-aza-2'-deoxycytidine, it requires high concentrations to be effective in DNA demethylation in suppressing cancer cell growth. Thus, our laboratories have embarked on the pharmacological exploitation of procainamide to develop potent DNA methylation inhibitors through lead optimization.</p> <p>Methods</p> <p>We report the use of a DNA methylation two-component enhanced green fluorescent protein reporter system as a screening platform to identify novel DNA methylation inhibitors from a compound library containing procainamide derivatives.</p> <p>Results</p> <p>A lead agent IM25, which exhibits substantially higher potency in <it>GSTp1 </it>DNA demethylation with lower cytotoxicity in MCF7 cells relative to procainamide and 5-aza-2'-deoxycytidine, was identified by the screening platform.</p> <p>Conclusions</p> <p>Our data provide a proof-of-concept that procainamide could be pharmacologically exploited to develop novel DNA methylation inhibitors, of which the translational potential in cancer therapy/prevention is currently under investigation.</p>http://www.jbiomedsci.com/content/18/1/3 |
| spellingShingle | Chen Ching-Shih Huang Tim HM Tseng Min-Jen Teng I-Wen Hsu Chia-Chen Wang Shi-Gang Shaw Arthur Y Lin Yi-Shiuan Leu Yu-Wei Hsiao Shu-Huei Identification of novel DNA methylation inhibitors via a two-component reporter gene system Journal of Biomedical Science |
| title | Identification of novel DNA methylation inhibitors via a two-component reporter gene system |
| title_full | Identification of novel DNA methylation inhibitors via a two-component reporter gene system |
| title_fullStr | Identification of novel DNA methylation inhibitors via a two-component reporter gene system |
| title_full_unstemmed | Identification of novel DNA methylation inhibitors via a two-component reporter gene system |
| title_short | Identification of novel DNA methylation inhibitors via a two-component reporter gene system |
| title_sort | identification of novel dna methylation inhibitors via a two component reporter gene system |
| url | http://www.jbiomedsci.com/content/18/1/3 |
| work_keys_str_mv | AT chenchingshih identificationofnoveldnamethylationinhibitorsviaatwocomponentreportergenesystem AT huangtimhm identificationofnoveldnamethylationinhibitorsviaatwocomponentreportergenesystem AT tsengminjen identificationofnoveldnamethylationinhibitorsviaatwocomponentreportergenesystem AT tengiwen identificationofnoveldnamethylationinhibitorsviaatwocomponentreportergenesystem AT hsuchiachen identificationofnoveldnamethylationinhibitorsviaatwocomponentreportergenesystem AT wangshigang identificationofnoveldnamethylationinhibitorsviaatwocomponentreportergenesystem AT shawarthury identificationofnoveldnamethylationinhibitorsviaatwocomponentreportergenesystem AT linyishiuan identificationofnoveldnamethylationinhibitorsviaatwocomponentreportergenesystem AT leuyuwei identificationofnoveldnamethylationinhibitorsviaatwocomponentreportergenesystem AT hsiaoshuhuei identificationofnoveldnamethylationinhibitorsviaatwocomponentreportergenesystem |